VCYTVeracyte, Inc.

Healthcare

$45.23+33% 1Y

$45.23

$30.0152 weeks$59.55

Price

+33%1Y

End-of-day closes, not the intraday tick.

More going right than wrong

Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.

RyuScore 28 of 100: see how it is built

What they do

At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/E32.3

Market value$4.67B

1 year+33%

5 years-3.6%

Charts

As reported to the SEC, without any scoring.

Veracyte, Inc. (VCYT) reported revenue of $150M in Q2 2026 (quarter ended Jun 30, 2026), up 15% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $25M (17% of revenue). For the full year FY2025, revenue was $517M (+16% year on year) and net income $66M. Its largest product in Q2 2026 was Testing at $146M, 96% of the disclosed total, well ahead of Testing Other at 3.0%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 14, 2026Merger Agreement On September 10, 2026, Veracyte, Inc., a Delaware corporation (“Veracyte”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Compass Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Veracyte (“Merger Sub”), Convergent Genomics Inc., a Delaware …Material agreement entered · Form 8-K
Mar 16, 2026On March 16, 2026, Veracyte, Inc. (the “Company”) announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.